Cadila Pharmaceuticals Limited
Overview
Cadila Pharmaceuticals Limited is one of the largest privately held pharmaceutical companies in India, committed to the development and commercialization of innovative therapeutic solutions. With a wide-ranging portfolio that spans numerous therapeutic areas, Cadila is dedicated to improving patient outcomes globally.
API / Drug Master Files
Cadila Pharmaceuticals Limited holds 32 active (58 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.
- GEIBROZIL USPActive2020-07-10
- HYDRALAZINE HYDROCHLORIDE USPActive2020-07-03
- VENLAFAXINE HYDROCHLORIDE USP (PROCESS-2)Active2015-09-23
- ARIPIPRAZOLE USPActive2015-09-11
- BUPROPION HYDROCHLORIDE USPActive2014-12-31
- CARVEDILOL USPActive2014-04-18
- ATORVASTATIN CALCIUM USP FORM-IActive2014-04-16
- PHTHALOYL AMLODIPINEActive2014-01-31
- NATEGLINIDE FORM H USPActive2013-06-21
- RALOXIFENE HYDROCHLORIDE USPActive2013-05-06
- BOSENTAN MONOHYDRATEActive2013-03-05
- VALSARTAN USP (PROCESS 2)Active2012-07-07
- PALIPERIDONE USPActive2010-11-29
- OLMESARTAN MEDOXOMIL USPActive2009-08-26
- ATOMOXETINE HYDROCHLORIDE USPActive2009-08-11
Showing 15 of 58 Drug Master Files.
FDA compliance signals
3 FDA enforcement records linked to this company.
- 4832018-05-03
Testing and release for distribution
- recall — Class II2016-12-07
Microbial Contamination of Non-Sterile Product
- warning_letter2014-10-15
FDA Warning Letter (drug product)
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.